URAT1 allele 6092(T/C) polymorphism influence uricosuric action of losartan in hyperuricemia patients with hypertension

Abstract

Abstract: AIM: To investigate the effect of URAT1 6092(T/C) polymorphism on uricosuric action of losartan in Chinese hyperuricemia patients with hypertension.METHODS: A total of 101 patients and 117 healthy controls were enrolled to identify 6092T/C genotypes by polymerase chain reaction restriction fragment length polymorphism assay.All patients received orally losartan as a single-dose therapy (100 mg/d p.o.) for 2 weeks. The blood pressure,serum creatinine(Cr), blood urea nitrogen (BUN),serum uric acid(Ur), total cholesterol(CHOL), high-density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c) and triglyceride(TG) were determined before and after losartan treatment.RESULTS: After treatment,patients with the T6092C polymorphism TC/CC genotype showed significant lower levels. Compared with patients with the TT genotype,the decreased value and percentage of Ur, Cr was low ,moreover, patients with CT/CC genotype also showed significant lower levels of decreased percentage of Ur (1.34%±2.12%,-0.2%±3.8%) compared with patients with the TT genotype (22.58%±14.46%)(P<0.05).CONCLUSION: These results suggest that URAT1 6092(T/C) polymorphism can influence the uricosuric action of losartan and it is potential genetic markers for the optimization of losartan uricosuric action.

Key words: losartan, URAT1, hyperuricemia, hypertension, polymorphism

CLC Number:

R968

HUANG Xu-hui, SUN Hong, CAI Jia-qin, JU Ming-yu. URAT1 allele 6092(T/C) polymorphism influence uricosuric action of losartan in hyperuricemia patients with hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 435-440.

References

[1] Hamada T, Hisatome I, Kinugasa Y, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects[J]. Intern Med,2002,41(10):793-797.
[2] Rayner BL, Trinder YA, Baines D, et al. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics[J].Am J Hypertens, 2006,19(2):208-213.
[3] Puig JG, Mateos F, Buno A, et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension[J].J Hypertens,1999,17(7):1033-1039.
[4] Schmitt F, Natov S, Martinez F, et al. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man[J]. Clin Sci,1996, 90(3): 205-213.
[5] Nishida Y, TakahashiY, Susa N, et al. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study[J].Cardiovasc diabetol,2013,12(1):159.doi: 10.1186/1475-2840-12-159.
[6] Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease[J]. Clin Exp nephrol, 2005,9(3):195-205.
[7] Iwanaga T, Sato M, Maeda T, et al. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter[J]. J Pharmacol Exp Ther, 2007, 320(1):211-217.
[8] Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles[J]. J Pharmacol Exp Ther,1997,280(2):839-845.
[9] Alderman MH, Cohen H, Madhavan S,et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients[J]. Hypertens,1999,34(1):144-150.
[10]Nindita Y,Hamada T,Bahrudin U. Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA[J]. Arzneimittelforschung,2010,60(4):186-188.
[11] Enomoto A, Niwa T, Kanai Y,et al.Urate transporter and renal hypouricemia[J]. Rinsho Byori,2003,51(9):892-897.
[12] Enomoto A, Kimura H, Chairoungdua A, et al.Molecular identification of a renal urate anion exchanger that regulates blood urate levels[J]. Nature,2002,417(6887):447-452.
[13] Jutabha P, Kanai Y, Hosoyamada M, et al.Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule[J]. J Biol Chem,2003,278(30):27930-27938.
[14] Ichida K, Hosoyamada M, Hisatome I, et al.Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion[J]. J Am Soc Nephrol,2004, 15(1) :164-173.
[15] Vázquez-Mellado J, Jiménez-Vaca AL, Cuevas-Covarrubias S, et al. Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout[J]. Rheumatology,2007,46(2):215-219.
[16] Tin A, Woodward OM, Kao WH, et al. Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele[J]. Hum Mol Genet, 2011,20(20):4056-4068.
[17] Graessler J, Graessler A, Unger S, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population[J]. Arthritis Rheum, 2006,54(1):292-300.
[18] Li C, Han L, Levin AM, et al. Multiple single nucleotide polymorphisms in the human urate transporter 1 (hURAT1) gene are associated with hyperuricaemia in Han Chinese[J]. J Med Genet,2010,47(3):204-210.
[19] Shima Y, Teruya K, Ohta H. Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese[J]. Life Sci,2006,79(23):2234-2237.
[20] Graessler J,Graessler A,Unger S,et al.Association of the human Urate Transporter 1 with reduced renal uric acid excretion and hyperuricemia in a german caucasian population[J].Arthritis Rheum, 2006,54(1):292-300.
[21] Jang WC, Nam YH, Park SM, et al.T6092C polymorphism of SLC22A12 gene is associated with serum uric acid concentrations in Korean male subjects[J].Clinica Chimica Acta,2008,398(1/2):140-144.
[22] Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients[J]. Am J Hypertens,2008,21(10):1157-1162.
[23] Zhu X, Chen J, Han F, et al. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study[J]. Transplant Proc,2009,41(9): 3736-3742.
[24] Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects[J]. Eur J Clin Pharmacol,1992,42(3):333-335.
[25] Sweet CS, Bradstreet DC, Berman RS,et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension[J]. Am J Hypertens, 1994, 7(12):1035-1040.
[26] Cardona F, Tinahones FJ, Collantes E,et al.The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates[J].Rheumatology (Oxford),2003,42(3):468-472.